Tetraphase Raises $45 Mil. In Series C Round, Enough To Finish Phase II For Next-Gen Antibiotic
This article was originally published in The Pink Sheet Daily
Tetraphase is keeping its exit options open, hoping for either an initial public offering, a licensing deal or an acquisition down the road.
You may also be interested in...
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
VCs see rich exit opportunities, especially for start-ups with multiple products in their pipelines. In this issue we profile four emerging antibiotic drug developers: Cempra Pharmaceuticals, DesignMedix, Kenta Biotech and MGB Biopharma.
Achaogen turns to VC backers to advance its lead compound into Phase II trials for complicated urinary tract infections.